$2.31
Oramed Pharmaceuticals is a biotechnology business based in the US. Oramed Pharmaceuticals shares (ORMP) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.32 – a decrease of 2.73% over the previous week.
What's in this guide?
- ORMP shares summary
- Compare share dealing platforms
- Is ORMP stock a buy or sell?
- Stock performance over time
- Can I short ORMP shares?
- Are ORMP shares over-valued?
- Oramed Pharmaceuticals's financials
- How volatile are ORMP shares?
- Does Oramed Pharmaceuticals pay a dividend?
- Have ORMP shares ever split?
- Other common questions
Our top picks for where to buy Oramed Pharmaceuticals stock
- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
- Trade $0 commission stocks & ETFs with as little as $1
- Theme and ETF screener
- Discover new opportunities with Opto's AI-driven classification system
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options, with no options contract fees
- Complimentary access to a financial planner and automated investing
How to buy Oramed Pharmaceuticals stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ORMP. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Oramed Pharmaceuticals stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Oramed Pharmaceuticals stock price (NASDAQ: ORMP)
Use our graph to track the performance of ORMP stocks over time.Oramed Pharmaceuticals shares at a glance
Latest market close | $2.32 |
---|---|
52-week range | $1.67 - $3.67 |
50-day moving average | $2.38 |
200-day moving average | $2.52 |
Wall St. target price | $3.25 |
PE ratio | 4.6078 |
Dividend yield | N/A |
Earnings per share (TTM) | $0.51 |
Is it a good time to buy Oramed Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Oramed Pharmaceuticals price performance over time
Historical closes compared with the close of $2.315 from 2024-10-18
1 week (2024-10-15) | -1.49% |
---|---|
1 month (2024-09-20) | 0.22% |
3 months (2024-07-22) | -10.62% |
6 months (2024-04-22) | -0.64% |
1 year (2023-10-20) | 12.93% |
---|---|
2 years (2022-10-21) | -66.30% |
3 years (2021-10-22) | 22.61 |
5 years (2019-10-22) | 3.13 |
Is Oramed Pharmaceuticals stock undervalued or overvalued?
Valuing Oramed Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Oramed Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Oramed Pharmaceuticals's P/E ratio
Oramed Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Oramed Pharmaceuticals shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Oramed Pharmaceuticals financials
Gross profit TTM | $2.7 million |
---|---|
Return on assets TTM | -4.72% |
Return on equity TTM | 12.7% |
Profit margin | 0% |
Book value | $4.36 |
Market Capitalization | $95.8 million |
TTM: trailing 12 months
Oramed Pharmaceuticals share dividends
We're not expecting Oramed Pharmaceuticals to pay a dividend over the next 12 months.
Have Oramed Pharmaceuticals's shares ever split?
Oramed Pharmaceuticals's shares were split on a 1:12 basis on 22 January 2013 . So if you had owned 12 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Oramed Pharmaceuticals shares – just the quantity. However, indirectly, the new 1100% higher share price could have impacted the market appetite for Oramed Pharmaceuticals shares which in turn could have impacted Oramed Pharmaceuticals's share price.
Oramed Pharmaceuticals share price volatility
Over the last 12 months, Oramed Pharmaceuticals's shares have ranged in value from as little as $1.67 up to $3.67. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Oramed Pharmaceuticals's is 1.762. This would suggest that Oramed Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Oramed Pharmaceuticals overview
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules for delivery of polypeptides. The company's product portfolio includes ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes, as well as in phase II clinical trial for the treatment of non-alcoholic steatohepatitis; and ORA-D-013-1 and ORA-D-013-2, which have completed phase II clinical trial for the treatment of type 2 diabetes. It has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York.
Frequently asked questions
What percentage of Oramed Pharmaceuticals is owned by insiders or institutions?Currently 11.448% of Oramed Pharmaceuticals shares are held by insiders and 16.508% by institutions. When does the fiscal year end for Oramed Pharmaceuticals?
Oramed Pharmaceuticals's fiscal year ends in December. Where is Oramed Pharmaceuticals based?
Oramed Pharmaceuticals's address is: 1185 Avenue of the Americas, New York, NY, United States, 10036 What is Oramed Pharmaceuticals's ISIN number?
Oramed Pharmaceuticals's international securities identification number is: US68403P2039 What is Oramed Pharmaceuticals's CUSIP number?
Oramed Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 68403P104
More guides on Finder
-
Fundamental Analysis
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Best broker cash sweep rates of 2024
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
Titan Review 2024: Wealth Management With a No-Advisory-Fee Robo-Advisor
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
-
Public.com Review 2024: No-Fee Options, With Rebates
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
-
How to trade options
Read our beginner’s guide to trading options in the US.
Ask a question